Alamar Biosciences, Inc. was incorporated in Delaware on May 7, 2018, and is headquartered in Fremont, California. The company is a commercial-stage proteomics company dedicated to establishing the gold standard in protein detection and analysis. It offers the proprietary NULISA platform, which enables "precision proteomics" by detecting low-abundance protein biomarkers in non-invasive biofluids with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range, and automation. The company provides integrated solutions comprising instruments, consumables, and analytical software for discovery, translational research, and diagnostic development.